BR0114510A - Fragmentos de polipeptìdeos do vìrus da hepatite e, composição de vacina e kits de diagnóstico compreendendo o mesmo e uso destes - Google Patents

Fragmentos de polipeptìdeos do vìrus da hepatite e, composição de vacina e kits de diagnóstico compreendendo o mesmo e uso destes

Info

Publication number
BR0114510A
BR0114510A BR0114510-0A BR0114510A BR0114510A BR 0114510 A BR0114510 A BR 0114510A BR 0114510 A BR0114510 A BR 0114510A BR 0114510 A BR0114510 A BR 0114510A
Authority
BR
Brazil
Prior art keywords
polypeptide
hepatitis
virus
present
vaccine composition
Prior art date
Application number
BR0114510-0A
Other languages
English (en)
Inventor
Ningshao Xia
Jun Zhang
Shaowei Li
Shengxiang Ge
Ying Gu
Zhiqiang He
Original Assignee
Yang Sheng Tang Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yang Sheng Tang Co Ltd filed Critical Yang Sheng Tang Co Ltd
Publication of BR0114510A publication Critical patent/BR0114510A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"FRAGMENTOS DE POLIPEPTìDEOS DO VìRUS DA HEPATITE E, COMPOSIçãO DE VACINA E KITS DE DIAGNóSTICO COMPREENDENDO O MESMO E USO DESTES". A presente invenção refere-se ao(s) polipeptídeo(s) compreendendo a seq³ência de aminoácido apresentada na SEQ.ID.NO:1 da ORF 2 do vírus da hepatite E ou seus fragmentos, o qual está na forma de polipeptídeo n-polimérico, onde n é um número inteiro de 1-180; uma proteína quimérica consistindo de um polipeptídeo da presente invenção e um fragmento conservado do antígeno hemaglutina do vírus influenza; um polipeptídeo da presente invenção ligado a um polipeptídeo contendo o epítopo da ORF3 do vírus da hepatite E, ou um fragmento imunogênico do mesmo; um vetor de expressão recombinante compreendendo a molécula de DNA codificando os polipeptídeos acima e a célula hospedeira transformada com o dito vetor de expressão recombinante que é capaz de expressar o polipeptídeo da presente invenção. A presente invenção refere-se adicionalmente a uma composição de vacina contra o vírus da hepatite E que compreende o polipeptídeo acima mencionado, ou kit de diagnóstico para infecção do vírus da hepatite E compreendendo o polipeptídeo acima mencionado, que inclui IgG, IgM, ou o kit de diagnóstico dos anticorpos totais para o vírus da hepatite E, e para o uso da composição da vacina e o kit de diagnóstico para profilaxia, diagnose e/ou tratamento da infecção por vírus da hepatite E.
BR0114510-0A 2000-09-30 2001-09-30 Fragmentos de polipeptìdeos do vìrus da hepatite e, composição de vacina e kits de diagnóstico compreendendo o mesmo e uso destes BR0114510A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN00130634A CN1345775A (zh) 2000-09-30 2000-09-30 用于预防、诊断及治疗戊型肝炎病毒的多肽,及它们作为诊断试剂和疫苗
PCT/CN2001/001469 WO2002040681A1 (fr) 2000-09-30 2001-09-30 Fragment polypeptidique du virus de l'hepatite e, composition vaccinale contenant ledit fragment, agent diagnostic et leurs applications

Publications (1)

Publication Number Publication Date
BR0114510A true BR0114510A (pt) 2004-02-17

Family

ID=4594225

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0114510-0A BR0114510A (pt) 2000-09-30 2001-09-30 Fragmentos de polipeptìdeos do vìrus da hepatite e, composição de vacina e kits de diagnóstico compreendendo o mesmo e uso destes
BRPI0114510 BRPI0114510B8 (pt) 2000-09-30 2001-09-30 multímero de polipeptídeo monomérico purificado, composição de vacina para profilaxia ou tratamento da infecção por vírus da hepatite e em mamíferos, kit de diagnóstico para infecção por vírus da hepatite e em amostras biológicas, método de diagnóstico in vitro da infecção por vírus da hepatite e em mamíferos, método para detecção in vitro de anticorpos totais contra o vírus da hepatite e em amostras biológicas, método para detecção in vitro do anticorpo igg contra o vírus da hepatite e em amostras biológicas e método para detectar in vitro o anticorpo igm contra o vírus da hepatite e em amostras biológicas

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0114510 BRPI0114510B8 (pt) 2000-09-30 2001-09-30 multímero de polipeptídeo monomérico purificado, composição de vacina para profilaxia ou tratamento da infecção por vírus da hepatite e em mamíferos, kit de diagnóstico para infecção por vírus da hepatite e em amostras biológicas, método de diagnóstico in vitro da infecção por vírus da hepatite e em mamíferos, método para detecção in vitro de anticorpos totais contra o vírus da hepatite e em amostras biológicas, método para detecção in vitro do anticorpo igg contra o vírus da hepatite e em amostras biológicas e método para detectar in vitro o anticorpo igm contra o vírus da hepatite e em amostras biológicas

Country Status (9)

Country Link
US (3) US7615228B2 (pt)
EP (2) EP1331271B1 (pt)
JP (3) JP5681337B2 (pt)
KR (2) KR101121754B1 (pt)
CN (2) CN101367869B (pt)
AU (1) AU2002220460A1 (pt)
BR (2) BR0114510A (pt)
MX (1) MXPA03002751A (pt)
WO (1) WO2002040681A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101367869B (zh) * 2000-09-30 2012-12-05 北京万泰生物药业股份有限公司 用于预防、诊断及治疗戊型肝炎病毒的多肽,及它们作为诊断试剂和疫苗
US7786264B2 (en) * 2001-11-08 2010-08-31 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd Monoclonal antibody against hepatitis E virus or its fragment with binding activity and use thereof
CN1850855B (zh) * 2006-05-26 2012-08-29 厦门大学 用于免疫或制备单克隆抗体的方法和组合物
US8906862B2 (en) 2009-02-27 2014-12-09 The Regents Of The University Of California Multiple antigen delivery system using hepatitis E virus-like particle
EP2400982B1 (en) * 2009-02-27 2016-05-11 The Regents of The University of California Multiple antigen delivery system using hepatitis e virus-like particle
US8906863B2 (en) 2009-02-27 2014-12-09 The Regents Of The University Of California Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector
WO2012028161A1 (en) * 2010-08-31 2012-03-08 Abb Technology Ag Method for debugging of process or manufacturing plant solutions comprising multiple sub-systems
CN102453748A (zh) * 2010-10-18 2012-05-16 北京雅康博生物科技有限公司 用于荧光定量pcr定量检测的质粒标准品
CN102565410B (zh) * 2012-01-12 2014-08-06 吉林大学 一种梅花鹿朊蛋白免疫学检测方法
ES2900401T3 (es) * 2012-05-09 2022-03-16 Bharat Biotech Int Ltd Combinaciones de vacunas
CN104031144B (zh) * 2013-03-05 2017-08-25 厦门大学 特异结合戊型肝炎病毒3、4型的抗体及其用途
CN104789534B (zh) * 2015-04-10 2017-10-17 浙江中医药大学 一种杂交瘤、单克隆抗体及其用途
FR3044312B1 (fr) * 2015-11-30 2017-12-08 Biomerieux Sa Polypeptides mutes de hev et leur utilisation pour le dosage d'anticorps anti-hev
US10512685B2 (en) * 2016-05-25 2019-12-24 Intervet Inc. HEV vaccine
KR101924093B1 (ko) 2017-04-18 2018-11-30 건국대학교 산학협력단 E형 간염 바이러스 유전자형 3 및 4 진단용 프라이머 세트 및 이를 이용한 진단 방법
CN110501505B (zh) * 2018-05-18 2022-06-10 中国兽医药品监察所 小反刍兽疫诊断试剂盒
CN112384530B (zh) * 2018-07-10 2024-02-06 国家医疗保健研究所 戊型肝炎病毒orf2i蛋白的表位肽
US20210324049A1 (en) * 2018-07-10 2021-10-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity for the orf2i protein of hepatitis e virus and uses thereof for diagnostic purposes
CN109942702B (zh) * 2019-03-20 2019-11-08 南京医科大学 一种人鼠嵌合抗HEV全分子IgG及其应用
JP7259622B2 (ja) 2019-07-29 2023-04-18 パナソニックホールディングス株式会社 冷却システム及びその運転方法
CN117730255A (zh) 2021-07-06 2024-03-19 株式会社先端生命科学研究所 E型肝炎病毒感染的检测方法、e型肝炎病毒感染检测用抗原多肽和试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219515A (en) 1987-02-10 1989-09-27 Wellcome Found Fusion proteins comprising influenza virus ha and a nonnatural antigenic epitope
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US5885768A (en) 1988-06-17 1999-03-23 The United States Of America As Represented By The Department Of Health And Human Services Hepatitis E virus peptide antigen and antibodies
US6214970B1 (en) 1988-06-17 2001-04-10 Genelabs Technologies, Inc. Hepatitis E virus antigens and uses therefor
US5714374A (en) * 1990-09-12 1998-02-03 Rutgers University Chimeric rhinoviruses
US5563032A (en) * 1992-10-21 1996-10-08 The United States Of America As Represented By The Department Of Health And Human Services Mosaic polypeptide and methods for detecting the hepatitis E virus
EP0736087A1 (en) 1993-12-22 1996-10-09 Abbott Laboratories Monoclonal antibodies against hev orf-2 and methods for using same
KR100359526B1 (ko) * 1994-10-03 2003-02-25 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 E형간염파키스탄형균주의재조합단백질및이를이용한진단방법과백신
AUPN443995A0 (en) 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
US6054567A (en) 1997-04-11 2000-04-25 The United States Of America As Represented By The Department Of Health And Human Services Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
DE19830896A1 (de) * 1998-07-10 2000-06-08 Mivatec Gmbh Fotoplott-Verfahren zur hochenergetischen Aufzeichnung eines computergespeicherten Rasterbildes auf einen lichtempfindlichen Aufzeichnungsträger
US6045567A (en) * 1999-02-23 2000-04-04 Lifescan Inc. Lancing device causing reduced pain
CA2283538A1 (en) 1999-09-30 2001-03-30 Mun Hon Ng New hev antigenic peptide and methods
CN101367869B (zh) * 2000-09-30 2012-12-05 北京万泰生物药业股份有限公司 用于预防、诊断及治疗戊型肝炎病毒的多肽,及它们作为诊断试剂和疫苗

Also Published As

Publication number Publication date
KR20090088429A (ko) 2009-08-19
CN101367869B (zh) 2012-12-05
EP1331271B1 (en) 2014-03-19
EP1331271A4 (en) 2005-04-06
WO2002040681A1 (fr) 2002-05-23
EP2298793A2 (en) 2011-03-23
US20040052813A1 (en) 2004-03-18
KR101121754B1 (ko) 2012-03-23
KR20030048052A (ko) 2003-06-18
JP5681337B2 (ja) 2015-03-04
US20100150962A1 (en) 2010-06-17
EP1331271A1 (en) 2003-07-30
BRPI0114510B8 (pt) 2021-05-25
JP2011201881A (ja) 2011-10-13
US7615228B2 (en) 2009-11-10
KR100927221B1 (ko) 2009-11-16
AU2002220460A1 (en) 2002-05-27
US8715695B2 (en) 2014-05-06
JP2014138593A (ja) 2014-07-31
MXPA03002751A (es) 2004-05-04
EP2298793A3 (en) 2011-06-29
JP2004525613A (ja) 2004-08-26
US20100143410A1 (en) 2010-06-10
US8524868B2 (en) 2013-09-03
CN1345775A (zh) 2002-04-24
CN101367869A (zh) 2009-02-18
JP5829830B2 (ja) 2015-12-09
BRPI0114510B1 (pt) 2019-09-03

Similar Documents

Publication Publication Date Title
BR0114510A (pt) Fragmentos de polipeptìdeos do vìrus da hepatite e, composição de vacina e kits de diagnóstico compreendendo o mesmo e uso destes
BRPI0214188B8 (pt) anticorpo ou fragmento do mesmo, molécula de ácido nucléico, uso do anticorpo monoclonal ou fragmento do mesmo, kit de diagnóstico, composição farmacêutica, vetor de expressão recombinante, célula hospedeira transformada com o vetor de expressão recombinante e método para detectar o antígeno do vírus da hepatite e ou o anticorpo contra o vírus da hepatite e em uma amostra
CN1609617B (zh) 诊断与预防严重急性呼吸道综合症（sars）的组合物和方法
Laver et al. Selection of antigenic mutants of influenza viruses. Isolation and peptide mapping of their hemagglutinating proteins
Zeng et al. Characterization of the 3a protein of SARS-associated coronavirus in infected vero E6 cells and SARS patients
KR910006889B1 (ko) 왁진 조성물
BR0015137A (pt) Peptìdeos antigênicos de neisseria
PT1090033E (pt) Particulas de proteinas de envelope do hcv: utilizacao para vacinacao
CN105693865A (zh) 包含白喉毒素无毒突变体crm197或其片段的融合蛋白
JP2008505050A (ja) Ｓａｒｓコロナウイルスｓタンパク質およびその使用
KR930702942A (ko) 재조합 고양이 코로나바이러스 에스 단백질
Watts et al. Mapping of the antigenic determinants of Pseudomonas aeruginosa PAK polar pili
BR112023016617A2 (pt) Polipeptídeo, conjugado do polipeptídeo, vacina para a prevenção de infecção pelo vírus da imunodeficiência humana 1, vacina para o uso na prevenção de infecção pelo vírus da imunodeficiência humana 1, sequência de ácido desoxirribonucleico complementar, e, célula hospedeira
AU726689B2 (en) Polypeptides corresponding to the amino acid sequences of proteins p57 or p9.5 of Borna disease virus, nucleic acid fragments coding therefore and their use for diagnostic and immunization purposes
Guillén et al. Expression in Escherichia coli of the lpdA gene, protein sequence analysis and immunological characterization of the P64k protein from Neisseria meningitidis
PT680765E (pt) Vacina para estirpe não tipável de haemophilus influenzae.
EP1294891A2 (en) Transport peptides derived from erns protein, cytotoxic rnase of ribosome-inactivating protein or a rsv g-protein and analogues thereof
AU2001269616A1 (en) Transport peptides derived from Erns protein, cytotoxic RNase of ribosome-inactivating protein or a RSV G-protein and analogues thereof
ES2281179T3 (es) Nuevos peptidos del virus de la hepatitis c y usos de los mismos.
BRPI0014390B1 (pt) Peptídeo isolado e purificado, protína de fusão recombinante, vetor, célula hospedeira, método para gerar o peptídeo, composição de vacina, método para determinar a presença ou ausência de anticorpos hev, kit de teste de diagnóstico, e, reagente de diagnóstico.
CA2277999C (en) The 74 kilodalton outer membrane protein from moraxella catarrhalis
EP0266325B1 (en) Bordetella pertussis polypeptides and toxin antigens
JP2024502783A (ja) コロナウイルスワクチン
EP3892298A1 (en) Epitopes having sequence homology to coronavirus spike protein subunit and uses thereof
ATE366583T1 (de) Identifizierung von spezifischen differenziell exprimierten antigenen aus mycobacterium und medizinische verwendung der mycobakteriumproteine rv0068 und rv3407

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO.,

Free format text: TRANSFERIDO DE: YANG SHENG TANG COMPANY LTD.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C12N 15/51

Ipc: C07K 14/02 (2006.01), C12N 15/51 (2006.01), A61K 3

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/09/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2690 DE 26/07/2022 POR TER SIDO INDEVIDA.